Core Insights - Agilent Technologies, Inc. is recognized as one of the 10 stocks that could see significant growth by 2026 [1] - The company reported Q1 2026 revenue of $1.8 billion, with core revenue growth of 4.4% year-over-year and reported growth of 7.0%, aided by a 2.6% currency tailwind [3] - Agilent reaffirmed its full-year FY26 core revenue growth guidance of 4%–6% and increased its EPS range to $5.90–$6.04, indicating confidence in steady margin expansion and resilient demand [3] Financial Performance - Q1 2026 operating cash flow was $268 million, with capital expenditures of $93 million [3] - The company returned $152 million to shareholders through share repurchases and $72 million in dividends during the quarter [3] - Agilent maintained a net leverage ratio of 0.8x, preserving financial flexibility for continued shareholder returns and potential acquisitions [3] Analyst Ratings and Price Targets - Baird lowered its price target on Agilent to $155 from $165 while maintaining an Outperform rating after Q4 results that were modestly below expectations [2] - TD Cowen reduced its price target to $157 from $170 but reiterated a Buy rating, noting that first-quarter results were affected by East Coast snowstorms [2]

Core Viewpoint - Thermo Fisher Scientific Inc. is poised to report strong quarterly earnings, with anticipated growth in both earnings per share and revenue, reflecting its robust market position and demand for its products [1][2]. Financial Performance - Analysts expect Thermo Fisher to report an earnings per share (EPS) of $6.43, representing a 5.4% increase from the same period last year [2][6]. - Projected revenue is approximately $11.94 billion, indicating a 4.8% year-over-year growth [2][6]. Market Reactions - There has been a slight downward revision of 0.1% in the consensus EPS estimate over the past month, which may influence short-term stock price movements [3]. Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 35.90, indicating strong investor confidence in future growth prospects [4][6]. - The price-to-sales (P/S) ratio stands at about 5.36, reflecting the value placed on each dollar of sales [4][6]. - The enterprise value to sales ratio is around 6.13, and the enterprise value to operating cash flow ratio is approximately 35.04, highlighting the company's valuation in relation to its sales and cash flow [5]. Financial Health - Thermo Fisher maintains a debt-to-equity ratio of approximately 0.70, indicating a moderate level of debt compared to its equity [5]. - A current ratio of about 1.50 suggests good liquidity to cover short-term liabilities [5].